Converge Bio Raises $25M, Backed By Bessemer and Execs from Meta, OpenAI, Wiz

Converge Bio Raises $25M, Backed By Bessemer and Execs from Meta, OpenAI, Wiz

Converge Bio Raises $25M to Accelerate AI-Driven Drug Discovery In a major vote of confidence for AI in biotech, Converge Bio has secured $25 million in Series A funding to fast-track its mission of transforming drug discovery. Backed by Bessemer Venture Partners and executives from Meta, OpenAI, and Wiz, the Boston- and Tel Aviv-based startup is using generative AI trained on molecular data to cut years off traditional R&D timelines—answering a critical need as pharma companies grapple with soaring costs and high failure rates. Credit: Bevan Goldswain / Getty Images Why AI-Driven Drug Discovery Is Heating Up The race to integrate artificial intelligence into pharmaceutical research is accelerating. With over 200 startups now vying to reshape how drugs are discovered, investors see a rare convergence of scientific breakthroughs and scalable tech. Converge Bio stands out by focusing not just on prediction, but on generation —creating novel biological candidates rather than merely analyz…